- Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis
- Connective Tissue Growth Factor
- Dermal Fibroblast
- Hypertrophic Scar
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Unable to display preview. Download preview PDF.
Razzaque MS, Ahmed AR. Collagens, collagen-binding heat shock protein 47 and transforming growth factorbeta 1 are induced in cicatricial pemphigoid: possible role(s) in dermal fibrosis. Cytokine 2002;17:311–6.
Ricard-Blum S, Hartmann DJ, Esterre P. Monitoring of extracellular matrix metabolism and cross-linking in tissue, serum and urine of patients with chromoblastomycosis, a chronic skin fibrosis. Eur J Clin Invest 1998;28:748–54.
Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007;127:281–92.
Zhou X, Tan FK, Xiong M, et al. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001;167:7126–33.
Whitfield ML, Finlay DR, Murray JI, Troyanskaya, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319–24.
Degiorgio-Miller AM, Treharne LJ, McAnulty RJ, et al. Procollagen type I gene expression and cell proliferation are increased in lipodermatosclerosis. Br J Dermatol 2005;152:242–9.
Herouy Y, May AE, Pornschlegel G, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998;111:822–7.
Quatresooz P, Henry F, Paquet P, et al. Deciphering the impaired cytokine cascades in chronic leg ulcers (review). Int J Mol Med 2003;11:411–8.
Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003;15:772–7.
Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003;14:537–50.
Atamas SP. Complex cytokine regulation of tissue fibrosis. Life Sci 2002;72:631–43.
Jelaska A, Strehlow D, Korn JH. Fibroblast heterogeneity in physiological conditions and fibrotic disease. Springer Semin Immunopathol 1999;21:385–95.
Tan FK, Arnett FC, Reveille JD, et al. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000;43:2464–71.
Zhou X, Tan FK, Milewicz DM, et al. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the “scleroderma phenotype.” J Immunol 2005;175:4555–60.
Kuwana M, Kaburaki J, Medsger TA Jr, et al. An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera. Arthritis Rheum 1999;42:1179–88.
Henry PA, Atamas S P, Yurovsky V V, et al. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum 2000;43:2733–42.
Warrington KJ, Nair U, Carbone LD, et al. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther 2006;8:R136.
Hu PQ, Oppenheim JJ, Medsger TA Jr, et al. T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 2006;26:258–67.
Marie I, Cordel N, Lenormand B, et al. Clonal T cells in the blood of patients with systemic sclerosis. Arch Dermatol 2005;141:88–9.
Sakkas LI, Xu B, Artlett CM, et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649–59.
Skert C, Patriarca F, Sperotto A, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006;91:258–61.
Schaffer JV, McNiff JM, Seropian S, et al. Lichen sclerosus and eosinophilic fasciitis as manifesta-tions of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005;53:591–601.
Zhang Y, McCormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088– 98.
Kaplan DH, Anderson BE, McNiff JM, et al. Target antigens determine graft-versus-host disease pheno-type. J Immunol 2004;173:5467–75.
Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660–6.
Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569–77.
Tredget EE, Yang L, Delehanty M, et al. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res 2006;26:179–89.
Liu W, Ding I, Chen K, et al. Interleukin 1beta (IL1B) signaling is a critical component of radiationinduced skin fibrosis. Radiat Res 2006;165:181–91.
Martin M, Lefaix JL, Pinton P, et al. Temporal modulation of TGF-beta 1 and beta-actin gene expression in pig skin and muscular fibrosis after ionizing radiation. Radiat Res 1993;134:63–70.
Lafuma C, El Nabout RA, Crechet F, et al. Expression of 72-kDa gelatinase (MMP-2), collagenase (MMP1), and tissue metalloproteinase inhibitor (TIMP) in primary pig skin fibroblast cultures derived from radiation-induced skin fibrosis. J Invest Dermatol 1994;102:945–50.
Flanders KC, Sullivan CD, Fujii M, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002;160:1057–68.
Saito E, Fujimoto M, Hasegawa M, et al. CD19dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109:1453–62.
Muryoi T, Kasturi KN, Kafina MJ, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992;175:1103–9.
Wang HW, Tedla N, Hunt JE, et al. Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 2005;14:295–302.
Kodera T, McGaha TL, Phelps R, et al. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 2002;99:3800–5.
McGaha TL, Le M, Kodera T, et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum 2003;48:2275–84.
McGaha T, Saito S, Phelps RG, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001;116:136–43.
Christner PJ, Hitraya EG, Peters J, et al. Transcriptional activation of the alpha1(I) procollagen gene and upregulation of alpha1(I) and alpha1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice. Arthritis Rheum 1998;41:2132–42.
Christner PJ, Peters J, Hawkins D, et al. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration Arthritis Rheum 1995;38:1791–8.
Gentiletti J, McCloskey LJ, Artlett CM, et al. Demonstration of autoimmunity in the tight skin2 mouse: a model for scleroderma. J Immunol 2005;175:2418–26.
Wallace VA, Kondo S, Kono T, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994;24:1463–6.
Wooley PH, Sud S, Langendorfer A, et al. T cells infiltrating the skin of Tsk2 scleroderma-like mice exhibit T cell receptor bias. Autoimmunity 1998;27:91–8.
Sugerman PB, Faber SB, Willis LM, et al. Kinetics of gene expression in murine cutaneous graft-versushost disease. Am J Pathol 2004;164:2189–202.
Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004;122:44–50.
Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510–6.
Takagawa S, Lakos G, Mori Y, et al. Sustained activation of fibroblast transforming growth factor-beta/ Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003;121:41–50.
Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165:203–17.
Atamas SP. Alternative splice variants of cytokines: making a list. Life Sci 1997;61:1105–12.
Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004;16:733–8.
Chesney J, Metz C, Stavitsky AB, et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998;160:419–25.
Yang L, Scott PG, Dodd C, et al. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005;13:398–404.
Ishii G, Sangai T, Sugiyama K, et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 2005;23:699–706.
Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001;31:2936–41.
Yamamoto T, Eckes B, Mauch C, et al. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000;164:6174–9.
Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006;168:499–510.
Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005;175:7708–18.
Asano Y, Ihn H, Yamane K, et al. Impaired Smad7– Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004;113:253–64.
Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000;4310:2230–9.
Moulin V, Larochelle S, Langlois C, et al. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 2004;198:350–8.
Chizzolini C, Rezzonico R, Ribbens C, et al. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998;41:2039–47.
Chizzolini C, Parel Y, De Luca C, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003;48:2593–604.
Ong C, Wong C, Roberts CR, et al. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998;28:2619–29.
Atamas SP. FCP (http://fibro.biobitfield.com/fcp. php): a bioinformatic tool assisting in PubMed searches for literature on fibrosis-related cytokines. Arthritis Rheum 2003;48:2083–4.
Atamas SP, Luzina IG, Dai H, et al. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002;168:1139–45.
Atamas SP, Yurovsky V V, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168–78.
Rezzonico R, Burger D, Dayer JM. Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines. J Biol Chem 1998;273:18720–8.
De Palma R, Del Galdo F, Lupoli S, et al. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 2006;144:169–76.
Hasegawa M, Hamaguchi Y, Yanaba K, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954–66.
Sato S, Hasegawa M, Fujimoto M, et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635–43.
Yamamoto T, Hartmann K, Eckes B, et al. Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis. J Dermatol Sci 2001;26:106–11.
Trautmann A, Krohne G, Brocker EB, et al. Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4. J Immunol 1998;160:5053–7.
Kakizoe E, Shiota N, Tanabe Y, et al. Isoform-selective upregulation of mast cell chymase in the development of skin fibrosis in scleroderma model mice. J Invest Dermatol 2001;116:118–23.
Abe M, Kurosawa M, Ishikawa O, et al. Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J Allergy Clin Immunol 2000;106:S78–84.
Shephard P, Martin G, Smola-Hess S, et al. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 2004;164:2055–66.
Bellemare J, Roberge CJ, Bergeron D, et al. Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars. J Pathol 2005;206:1–8.
Funayama E, Chodon T, Oyama A, et al. Keratinocytes promote proliferation and inhibit apoptosis of the under-lying fibroblasts: an important role in the pathogenesis of keloid. J Invest Dermatol 2003;121:1326–31.
Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006;208:336–43.
Sivan V, Vozenin-Brotons MC, Tricaud Y, et al. Altered proliferation and differentiation of human epidermis in cases of skin fibrosis after radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:385–93.
Gharaee-Kermani M, Phan SH. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des 2001;7:1083–103.
McCormick LL, Zhang Y, Tootell E, et al. AntiTGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693–9.
Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2003;21:713–9.
Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005;125:450–5.
Wang XJ, Han G, Owens P, et al. Role of TGFbetamediated inflammation in cutaneous wound healing. J Invest Dermatol 2006;126:112–7.
Hakkinen L, Koivisto L, Gardner H, et al. Increased expression of beta6–integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol 2004;164:229–42.
Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964–78.
Gao Z, Wang Z, Shi Y, et al. Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. Plast Reconstr Surg 2006;118:1328–37.
Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311–22.
Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006;281:21183–97.
Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908–13.
Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004;122:1–6.
Holmes A, Abraham DJ, Chen Y, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 2003;278:41728–33.
Mori T, Kawara S, Shinozaki M, et al. J Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. Cell Physiol 1999;181:153–9.
Jinnin M, Ihn H, Yamane K, et al. Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004;279:41783–91.
Granel B, Chevillard C, Allanore Y, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006;58:693–9.
Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779–84.
Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibrob-last differentiation. Arthritis Rheum 2005;52:3772–82.
Distler JH, Jungel A, Caretto D, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214–25.
Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665–78.
Luzina IG, Atamas SP, Wise R, et al. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002;26:549–57.
Luzina IG, Highsmith K, Pochetuhen K, et al. PKCalpha mediates CCL18–stimulated collagen production in pulmonary fibroblasts. Am J Respir Cell Mol Biol 2006;35:298–305.
Luzina IG, Tsymbalyuk N, Choi J, et al. CCL18– stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006;206:221–8.
Atamas SP, Luzina IG, Choi J, et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003;29:743–9.
Luzina IG, Papadimitriou JC, Anderson R, et al. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte- dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum 2006;54:2643–55.
Mori R, Kondo T, Ohshima T, et al. Accelerated wound healing in tumor necrosis factor receptor p55–deficient mice with reduced leukocyte infiltration. FASEB J 2002;16:963–74.
Lee RH, Efron DT, Tantry U, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen 2000;8:547–53.
Kouba DJ, Nakano H, Nishiyama T, et al. Tumor necrosis factor-alpha induces distinctive NF-kappa B signaling within human dermal fibroblasts. J Biol Chem 2001;276:6214–24.
Yamane K, Ihn H, Asano Y, et al. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol 2003;171:3855–62.
Verrecchia F, Pessah M, Atfi A, et al. Tumor necrosis factor-alpha inhibits transforming growth factor-beta /Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000;275:30226–31.
Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220–5.
Ghosh AK, Bhattacharyya S, Mori Y, et al. Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). J Cell Physiol 2006;207:251–60.
Ghosh AK, Yuan W, Mori Y, et al. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001;276:11041–8.
Higashi K, Inagaki Y, Fujimori K, et al. Interferongamma interferes with transforming growth factorbeta signaling through direct interaction of YB-1 with Smad3. J Biol Chem 2003;278:43470–9.
Ishida Y, Kondo T, Takayasu T, et al. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 2004;172:1848–55.
Hasegawa T, Nakao A, Sumiyoshi K, et al. IFNgamma fails to antagonize fibrotic effect of TGF-beta on keloid-derived dermal fibroblasts. J Dermatol Sci 2003;32:19–24.
Hunzelmann N, Anders S, Fierlbeck G, et al. Doubleblind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997;36:433–5.
Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125–33.
Bolinger AM, Taeubel MA. Recombinant interferon gamma for treatment of chronic granulo-matous disease and other disorders. Clin Pharm 1992;11:834–50.
Virtual Round Table on ten leading questions for network research. Eur Phys J [B] 2004;38:143–5.
Feldmann M, Bondeson J, Brennan FM, et al. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? Ann Rheum Dis 1999;58:I27–31.
Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323–33.
Editors and Affiliations
Rights and permissions
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Luzina, I.G., Atamas, S.P. (2008). Fibrotic Skin Diseases. In: Gaspari, A.A., Tyring, S.K. (eds) Clinical and Basic Immunodermatology. Springer, London. https://doi.org/10.1007/978-1-84800-165-7_41
Publisher Name: Springer, London
Print ISBN: 978-1-84800-164-0
Online ISBN: 978-1-84800-165-7
eBook Packages: MedicineMedicine (R0)